CA2991109A1 - Compositions et procedes d'administration d'outils d'edition de gene au moyen de vesicules de polymere - Google Patents
Compositions et procedes d'administration d'outils d'edition de gene au moyen de vesicules de polymere Download PDFInfo
- Publication number
- CA2991109A1 CA2991109A1 CA2991109A CA2991109A CA2991109A1 CA 2991109 A1 CA2991109 A1 CA 2991109A1 CA 2991109 A CA2991109 A CA 2991109A CA 2991109 A CA2991109 A CA 2991109A CA 2991109 A1 CA2991109 A1 CA 2991109A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- dna
- gene editing
- poly
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010362 genome editing Methods 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 35
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 77
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 71
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 71
- 235000004252 protein component Nutrition 0.000 claims abstract description 28
- 229920001059 synthetic polymer Polymers 0.000 claims abstract description 17
- 238000012239 gene modification Methods 0.000 claims abstract description 6
- 230000005017 genetic modification Effects 0.000 claims abstract description 5
- 235000013617 genetically modified food Nutrition 0.000 claims abstract description 5
- 102000053602 DNA Human genes 0.000 claims description 131
- 108020004414 DNA Proteins 0.000 claims description 131
- 229920000575 polymersome Polymers 0.000 claims description 108
- -1 poly(ethylene oxide) Polymers 0.000 claims description 82
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 238000005538 encapsulation Methods 0.000 claims description 62
- 101710163270 Nuclease Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 235000018102 proteins Nutrition 0.000 claims description 42
- 229920000642 polymer Polymers 0.000 claims description 41
- 229920002477 rna polymer Polymers 0.000 claims description 40
- 108091033409 CRISPR Proteins 0.000 claims description 39
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 108090000790 Enzymes Proteins 0.000 claims description 37
- 108020005004 Guide RNA Proteins 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 26
- 108010020764 Transposases Proteins 0.000 claims description 22
- 102000008579 Transposases Human genes 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 230000008439 repair process Effects 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 18
- 230000000750 progressive effect Effects 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 13
- 230000033616 DNA repair Effects 0.000 claims description 12
- 229920001400 block copolymer Polymers 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 11
- 229920000359 diblock copolymer Polymers 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 9
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 229940065514 poly(lactide) Drugs 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 108091029865 Exogenous DNA Proteins 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 60
- 230000017854 proteolysis Effects 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 15
- 238000011068 loading method Methods 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000005782 double-strand break Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 9
- 241000702421 Dependoparvovirus Species 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000006703 hydration reaction Methods 0.000 description 9
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 102100030856 Myoglobin Human genes 0.000 description 8
- 108010062374 Myoglobin Proteins 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229910052697 platinum Inorganic materials 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 6
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 6
- 102000018120 Recombinases Human genes 0.000 description 6
- 108010091086 Recombinases Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000006780 non-homologous end joining Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108091028113 Trans-activating crRNA Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 108091079001 CRISPR RNA Proteins 0.000 description 4
- 102000012330 Integrases Human genes 0.000 description 4
- 108010061833 Integrases Proteins 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229920006237 degradable polymer Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 240000007019 Oxalis corniculata Species 0.000 description 3
- 238000004224 UV/Vis absorption spectrophotometry Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000012361 double-strand break repair Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002961 polybutylene succinate Polymers 0.000 description 3
- 239000004631 polybutylene succinate Substances 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- 108091028732 Concatemer Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004756 chromatid Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013636 protein dimer Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 108091064358 Holliday junction Proteins 0.000 description 1
- 102000039011 Holliday junction Human genes 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920000475 Poly(ethylene oxide)-block-polycaprolactone Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- QPADNTZLUBYNEN-UHFFFAOYSA-N etallobarbital Chemical compound C=CCC1(CC)C(=O)NC(=O)NC1=O QPADNTZLUBYNEN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
La présente invention concerne une composition pour modification génétique et un procédé de formation de la composition, la composition pouvant comprendre une vésicule de polymère synthétique, et un système d'édition de gène encapsulé dans la vésicule de polymère synthétique. Le système d'édition de gène peut comprendre un composant protéique et un composant d'acide nucléique configuré pour interagir avec une séquence cible dans un génome de cellule hôte.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187942P | 2015-07-02 | 2015-07-02 | |
US62/187,942 | 2015-07-02 | ||
US201662322346P | 2016-04-14 | 2016-04-14 | |
US62/322,346 | 2016-04-14 | ||
US15/199,021 US20170000743A1 (en) | 2015-07-02 | 2016-06-30 | Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles |
US15/199,021 | 2016-06-30 | ||
PCT/US2016/040673 WO2017004509A1 (fr) | 2015-07-02 | 2016-07-01 | Compositions et procédés d'administration d'outils d'édition de gène au moyen de vésicules de polymère |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2991109A1 true CA2991109A1 (fr) | 2017-01-05 |
Family
ID=57609243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2991109A Pending CA2991109A1 (fr) | 2015-07-02 | 2016-07-01 | Compositions et procedes d'administration d'outils d'edition de gene au moyen de vesicules de polymere |
Country Status (8)
Country | Link |
---|---|
US (1) | US20170000743A1 (fr) |
EP (1) | EP3317414A4 (fr) |
JP (2) | JP6993966B2 (fr) |
CN (1) | CN108699563A (fr) |
AU (1) | AU2016288237B2 (fr) |
CA (1) | CA2991109A1 (fr) |
HK (1) | HK1255209A1 (fr) |
WO (1) | WO2017004509A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
ES2865481T3 (es) * | 2016-04-29 | 2021-10-15 | Poseida Therapeutics Inc | Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos |
EP3519561A1 (fr) | 2016-09-30 | 2019-08-07 | Poseida Therapeutics, Inc. | Cellules t de mémoire de cellules souches modifiées, procédés de fabrication et procédés d'utilisation correspondants |
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
WO2018068022A1 (fr) | 2016-10-06 | 2018-04-12 | Poseida Therapeutics, Inc. | Caspases inductibles et procédés d'utilisation |
US20200384130A1 (en) | 2017-06-14 | 2020-12-10 | Dana-Farber Cancer Institute, Inc. | B-cell maturation antigen (bcma)-directed nanoparticles |
CA3067382A1 (fr) | 2017-06-15 | 2018-12-20 | The Regents Of The University Of California | Insertions ciblees d'adn non viral |
US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
BR112020008201A2 (pt) | 2017-10-27 | 2020-10-06 | The Regents Of The University Of California | substituição-alvo de receptores de células t endógenos |
EP3898993A1 (fr) | 2018-12-20 | 2021-10-27 | Poseida Therapeutics, Inc. | Compositions de nanotransposons et procédés d'utilisation |
EP4025593A1 (fr) | 2019-09-05 | 2022-07-13 | Poseida Therapeutics, Inc. | Compositions de cellules allogéniques et procédés d'utilisation |
WO2021127505A1 (fr) | 2019-12-20 | 2021-06-24 | Poseida Therapeutics, Inc. | Compositions anti-muc1 et méthodes d'utilisation |
US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
GB202004254D0 (en) | 2020-03-24 | 2020-05-06 | Puridify Ltd | Characterization of gene therapy vectors |
US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
AU2022257004A1 (en) * | 2021-04-13 | 2023-11-23 | Arsenal Biosciences, Inc. | Non-viral homology mediated end joining |
WO2023060088A1 (fr) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Compositions de transposons et leurs procédés d'utilisation |
WO2023164573A1 (fr) | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Cellules modifiées et leurs procédés d'utilisation |
WO2023193665A1 (fr) * | 2022-04-07 | 2023-10-12 | 威海纽兰生物科技有限公司 | Vecteur pour l'administration de médicament sensible à l'estérase à base de vésicule extracellulaire, son procédé de préparation et son utilisation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001261732A1 (en) | 2000-05-19 | 2001-12-03 | Betsy T. Kren | Composition for delivery of compounds to cells |
US20040265835A1 (en) * | 2003-06-30 | 2004-12-30 | Lemaster David M. | Method of sorting vesicle-entrapped, coupled nucleic acid-protein displays |
CA2756670A1 (fr) * | 2009-03-26 | 2010-09-30 | The Regents Of The University Of California | Cellules souches mesenchymateuses produisant de l'arn inhibiteur pouvant etre utilisees pour agir sur le cours d'une maladie |
KR101701534B1 (ko) * | 2009-04-07 | 2017-02-01 | 다우 아그로사이언시즈 엘엘씨 | 서열 특이적 뉴클레아제의 나노입자 매개 전달 |
WO2011106376A2 (fr) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Utilisation de microvésicules dans le traitement d'affections médicales |
WO2011109512A1 (fr) * | 2010-03-02 | 2011-09-09 | Vindico Nanobio Technology, Inc. | Compositions et méthodes de traitement prophylactique ou thérapeutique d'une pathologie immuno-inflammatoire |
US20140363496A1 (en) * | 2011-01-07 | 2014-12-11 | Vindico NanoBio Technology Inc. | Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors |
BR112013025567B1 (pt) * | 2011-04-27 | 2021-09-21 | Amyris, Inc | Métodos para modificação genômica |
SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
JP6552965B2 (ja) | 2012-12-12 | 2019-07-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化 |
WO2014150624A1 (fr) * | 2013-03-14 | 2014-09-25 | Caribou Biosciences, Inc. | Compositions et procédés pour des acides nucléiques à ciblage d'acide nucléique |
US20150067922A1 (en) * | 2013-05-30 | 2015-03-05 | The Penn State Research Foundation | Gene targeting and genetic modification of plants via rna-guided genome editing |
CA2951707A1 (fr) * | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Procede d'edition genique |
-
2016
- 2016-06-30 US US15/199,021 patent/US20170000743A1/en not_active Abandoned
- 2016-07-01 WO PCT/US2016/040673 patent/WO2017004509A1/fr active Application Filing
- 2016-07-01 EP EP16818879.5A patent/EP3317414A4/fr active Pending
- 2016-07-01 CA CA2991109A patent/CA2991109A1/fr active Pending
- 2016-07-01 AU AU2016288237A patent/AU2016288237B2/en active Active
- 2016-07-01 JP JP2018520385A patent/JP6993966B2/ja active Active
- 2016-07-01 CN CN201680050998.3A patent/CN108699563A/zh active Pending
-
2018
- 2018-11-09 HK HK18114337.3A patent/HK1255209A1/zh unknown
-
2019
- 2019-06-05 JP JP2019105213A patent/JP2019165745A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6993966B2 (ja) | 2022-02-04 |
HK1255209A1 (zh) | 2019-08-09 |
AU2016288237B2 (en) | 2022-04-14 |
CN108699563A (zh) | 2018-10-23 |
EP3317414A1 (fr) | 2018-05-09 |
JP2019165745A (ja) | 2019-10-03 |
AU2016288237A1 (en) | 2018-01-25 |
EP3317414A4 (fr) | 2019-03-13 |
US20170000743A1 (en) | 2017-01-05 |
WO2017004509A1 (fr) | 2017-01-05 |
JP2018532408A (ja) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016288237B2 (en) | Compositions and methods for delivery of gene editing tools using polymeric vesicles | |
EP3449004B1 (fr) | Micelles à base de poly (histidine) pour la complexation et l'administration de protéines et d'acides nucléiques | |
Wan et al. | Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook | |
Xu et al. | Delivery of CRISPR/Cas9 for therapeutic genome editing | |
Lee et al. | MicroRNA delivery through nanoparticles | |
Kauffman et al. | Materials for non-viral intracellular delivery of messenger RNA therapeutics | |
Givens et al. | Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics | |
Ryu et al. | Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy | |
Li et al. | Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities | |
Uchida et al. | Design concepts of polyplex micelles for in vivo therapeutic delivery of plasmid DNA and messenger RNA | |
Liu et al. | Responsive nanocarriers as an emerging platform for cascaded delivery of nucleic acids to cancer | |
Yin et al. | Non-viral vectors for gene-based therapy | |
WO2019126589A1 (fr) | Micelles pour la complexation et l'administration de protéines et d'acides nucléiques | |
JP2018532408A5 (fr) | ||
Ashok et al. | Lipid-and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9 | |
Sahel et al. | CRISPR/Cas9 genome editing for tissue‐specific in vivo targeting: nanomaterials and translational perspective | |
Khoshandam et al. | Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine | |
Yang et al. | Multivalent peptide-functionalized bioreducible polymers for cellular delivery of various RNAs | |
Hu et al. | Nanobiomaterial vectors for improving gene editing and gene therapy | |
Khirallah et al. | Clinical progress in genome-editing technology and in vivo delivery techniques | |
Shi et al. | Chemically Modified Platforms for Better RNA Therapeutics | |
Saw et al. | Nanoparticles‐Mediated CRISPR/Cas Gene Editing Delivery System | |
Kanduri et al. | Current advances toward the encapsulation of Cas9 | |
Lindsay-Mosher et al. | Cancer gene therapy: innovations in therapeutic delivery of CRISPR-Cas9 | |
Tuyen Ho et al. | Bioinspired and Biomimetic Gene Delivery Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |
|
EEER | Examination request |
Effective date: 20210628 |